Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab

Table 1 Patient baseline characteristics

	Cohort	Responders	Non-Responders	p-value
No. patients, n	46	19	27
No. eyes, n	52	22	30
Age, yr, mean ± SD	64.22 ± 8.12	63.61 ± 10.14	64.48 ± 6.79	0.3
Gender (M/F), n	(27/19)	(12/7)	(15/12)	0.6
Ethnicity, n (%)
African American	9 (19.6)	3 (15.8)	6 (22.2)	0.58
Asian	0 (0)	0 (0)	0 (0)
Hispanic	4 (8.7)	2 (10.5)	1 (3.7)	0.36
White	33 (71.7)	14 (73.7)	20 (74.1)	0.9
Diabetes mellitus (Type 1/Type 2), n	(0/46)	(0/19)	(0/27)
Disease duration*, yr, mean ± SD	18.47 ± 9.92	20.55 ± 12.08	16.6 ± 7.66	0.6
HbA1C^†, %, mean ± SD	8.05 ± 1.83	8.37 ± 2.26	7.82 ± 1.46	0.1
DR grade^§, no. eyes (%)
Mild NPDR	7 (16.6)	2 (11.8)	5 (20)	0.48
Moderate NPDR	11 (26.2)	4 (23.5)	7 (28)	0.75
Severe NPDR	13 (31)	8 (47)	5 (20)	0.06
PDR	11 (26.2)	3 (17.7)	8 (32)	0.3
BCVA (ETDRS letters), mean	63.9	60.9	66	0.09
CST (μm), mean ± SD	466 ± 123	560 ± 96	397 ± 90	< 0.001

HbA1C: Glycated hemoglobin level; DR: Diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy; BCVA: Best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; CST: Central subfield thickness
Data are presented as number (%) with p-values between responders and non-responders derived from respective Mann Whitney U tests and Chi-Square (χ²) analyses.
*Data included from 19 patients; ^†Data included from 37 patients; ^§Data included from 42 eyes

ISSN: 2056-9920